How do you pay?

How to pay the least

Ask for the cash price

VOXZOGO

We didn’t find one.

  1. Ask your pharmacy for VOXZOGO’s cash price, and one or two other pharmacies too.
  2. VOXZOGO’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameVOXZOGO
Authorized genericvosoritide
Regular genericvosoritide
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as VOXZOGO?
The original
–
–

Brand nameThe maker’s card

VOXZOGO Co-Pay Assistance Program (BioMarin RareConnections)

Savings card from BioMarin

No insuranceNeeds insuranceNo cash price listed.
Insurance $0 a prescription

The card takes up to $18,200 a year off your co-pay.

Sign up on biomarin-rareconnections.com 

Or call 1-833-869-9646.

In the maker’s words

“98% of commercially insured participants paid $0 out-of-pocket for their prescription…”

From the maker’s offer on biomarin-rareconnections.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is VOXZOGO itself, from the same company, sold without the brand name, and usually for less. For now VOXZOGO is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

VOXZOGO is a C type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Source: the FDA label for VOXZOGO (BioMarin Pharmaceutical Inc.), November 25, 2025. Full label on DailyMed 

Good to know